Eli Lilly’s Medicaid rebate payments under fire as whistleblower lawsuit heads to trialnews2022-03-01T19:46:05+00:00March 1st, 2022|Fierce Pharma|
A DOE-Based Approach to Optimizing T-Cell Expansionnews2022-03-01T19:16:51+00:00March 1st, 2022|Fierce Pharma|
BMS, Novartis, Akebia and more face FDA approval decisions soon, with big sales on the linenews2022-03-01T17:52:58+00:00March 1st, 2022|Fierce Pharma|
FibroGen’s roxadustat safety mess draws SEC scrutiny as AstraZeneca-partnered anemia drug remains in limbonews2022-03-01T16:25:23+00:00March 1st, 2022|Fierce Pharma|
Gilead’s HIV prospect lenacapavir hits FDA approval snag amid vial compatibility concernsnews2022-03-01T15:48:28+00:00March 1st, 2022|Fierce Pharma|
With sales sagging, Amarin sees progress on new Vascepa digital effort in the USnews2022-03-01T15:03:06+00:00March 1st, 2022|Fierce Pharma|
With Bayer’s new launches in infancy, Eylea and Xarelto still rule its pharma business—but for how long?news2022-03-01T15:01:59+00:00March 1st, 2022|Fierce Pharma|
CTI BioPharma clinches long-awaited FDA approval for myelofibrosis blockbuster prospect Vonjonews2022-03-01T14:57:23+00:00March 1st, 2022|Fierce Pharma|
FDA pushes back GC Pharma’s blood derivative approval due to inspection delaynews2022-03-01T14:56:34+00:00March 1st, 2022|Fierce Pharma|
Lung safety review delays FDA decision on United’s Tyvaso DPInews2022-03-01T14:40:16+00:00March 1st, 2022|Fierce Pharma|
